Astrazeneca (AZN) Net Cash Flow (2009 - 2026)
Astrazeneca (AZN) posted quarterly Net Cash Flow of -$5.5 billion for Q2 2026, down 246.16% year-over-year from $3.8 billion in Q2 2025, and down 260.92% quarter-over-quarter from -$1.5 billion in Q1 2026.
Astrazeneca (AZN) Net Cash Flow (2009 - 2026) Analysis & Trends
Astrazeneca's Net Cash Flow history runs 17 years deep, the most recent figure standing at -$5.5 billion for Q2 2026.
- In Q2 2026, Net Cash Flow fell 246.16% year-over-year to -$5.5 billion; the TTM figure through Jun 2026 stood at -$15.8 billion (up 3.3% YoY), while the FY2025 annual figure was $4.4 billion, up 11.04% from the prior year.
- Net Cash Flow for Q2 2026 stood at -$5.5 billion, down from -$1.5 billion in the prior quarter.
- The five-year high for Net Cash Flow was -$385.0 million in Q1 2024, with the low at -$6.6 billion in Q4 2023.
- The 5-year median for Net Cash Flow is -$4.0 billion (2025), against an average of -$3.8 billion.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow surged 88.25% in 2024, then slumped 928.57% in 2025.
- Astrazeneca's Net Cash Flow stood at -$6.5 billion in 2022, then fell by 1.58% to -$6.6 billion in 2023, then rose by 21.17% to -$5.2 billion in 2024, then grew by 8.67% to -$4.7 billion in 2025, then retreated by 16.41% to -$5.5 billion in 2026.
- Business Quant data shows AZN's Net Cash Flow at -$5.5 billion in Q2 2026, -$1.5 billion in Q1 2026, and -$4.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.82 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.53 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 757.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -6.80 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.95 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -4.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -722.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.68 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 27.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.50 Bn |
| Jun 30, 2026 | -5.50 Bn |
| Mar 31, 2026 | -1.53 Bn |
| Mar 31, 2026 | -1.53 Bn |
| Dec 31, 2025 | -4.73 Bn |
| Dec 31, 2025 | -4.73 Bn |
| Sep 30, 2025 | -4.07 Bn |
| Sep 30, 2025 | -4.07 Bn |
| Jun 30, 2025 | -1.59 Bn |
| Jun 30, 2025 | -1.59 Bn |
| Mar 31, 2025 | -3.96 Bn |
| Mar 31, 2025 | -3.96 Bn |
| Dec 31, 2024 | -5.18 Bn |
| Dec 31, 2024 | -5.18 Bn |
| Sep 30, 2024 | -5.65 Bn |
| Sep 30, 2024 | -5.65 Bn |
| Jun 30, 2024 | -4.09 Bn |
| Jun 30, 2024 | -4.09 Bn |
| Mar 31, 2024 | -385.00 Mn |
| Mar 31, 2024 | -385.00 Mn |